Insights
Insights From Our Experts
Articles
When A Curveball Threatens Your Product’s Launch
Download the article to learn about proven strategies to help shield your company from unwelcome surprises during launch by reducing your financial exposure and creating a more stable and flexible launch operation.
CBI Hub, SPP and eServices Insights: Leveraging Behavioral Health Technology
The Science of Human Resiliency — Behavioral Health Technology to Improve Patient Outcomes and Adherence Over the past several years, pharmaceutical manufacturers have been in pursuit of improving the patient experience by reducing time-to-treatment, developing a…
PharmaVOICE Commercial Influencers: Greg Skalicky
In a special focus on Commercial Influencers, PharmaVOICE Editor Taren Grom sat down with EVERSANA’s Chief Revenue Officer Greg Skalicky to discuss approaches to commercial strategies and how disruptive companies are changing the market to better reach and engage patients. The conversation covered commercialization trends, how…
Advancing Beyond the Traditional Patient Adherence Model
Showcase Featured In PharmaVOICE – October 2020 Delivering value in the era of empowered patients renders the one-size-fits all patient services program obsolete. Not every treatment journey is consistently linear within a disease state because patients…
Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard
Posted by Vikram Anand, Nina Patel Lahanis, Larry Davis, PharmD, Carolyn Quon, PharmD, Lisa Rinker, Thomas Barton on October 1, 202010/1/20
The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…
Trends in HTA Decisions
Alan Crowther and Dr. Magdi Stino explore trends in HTA decisions from the Pricentric HTA database for all therapeutic areas and within oncology. Examining over 25 HTA bodies from 2011 to 2019, they present findings on how…
WODC Insights: Developing HEOR Programs for Orphan Drugs
To successful launch a new orphan drug, demonstration of therapeutic success is crucial for a global HTA submission and securing market access. Manufacturers need to create a compelling value story with real-world data to illustrate how…
NEXT GENERATION COMMERCIALIZATION: A CONVERSATION WITH THE INNOVATORS
Sell, out-license or launch internally: these are the three traditional options to commercialize a pharmaceutical product. Selling and out-licensing are common but cause innovators to lose ownership in an investment that takes years to develop. Launching…
WODC 2020 Insights: Leveraging AI/ML to Advance Rare Diseases
Leveling the playing field The average time to correctly diagnose a patient with a rare disease is 7 years, largely due to data sparsity, misdiagnoses, incorrect prescriptions, etc. Now, through the application of artificial intelligence and…
Navigate the Complexity of Proposed CMS Medicaid Rule
In this presentation at MDRP’s virtual summit, Mike Kurland discusses several key regulatory proposals and executive orders and the impact on pharma: Operationalizing Value-Based Contracting – Has the door been opened, and how do we prepare…